Literature DB >> 12393460

Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo.

Xiaoyan Jiang1, Eddy Ng, Calvin Yip, Wolfgang Eisterer, Yves Chalandon, Matthew Stuible, Allen Eaves, Connie J Eaves.   

Abstract

Primitive chronic myeloid leukemia cells display a unique autocrine interleukin 3 (IL-3)/granulocyte-colony-stimluating factor (G-CSF) mechanism that may explain their abnormal proliferation and differentiation control. Here we show that BCR-ABL transduction of primitive Sca-1(+) lin(-) mouse bone marrow (BM) cells causes immediate activation of IL-3, G-CSF, and granulocyte macrophage-colony-stimulating factor (GM-CSF) expression in these cells. Their autocrine IL-3-mediated growth dependence is thus demonstrable only in clonal cultures where paracrine effects are reduced. Interestingly, upon continued culture, these cells produce large populations of rapidly proliferating mast cells in which only the IL-3 autocrine mechanism is consistently maintained, together with evidence of hyperphosphorylation of p210(BCR-ABL) and STAT5 and retention of a multilineage but attenuated in vivo leukemogenic potential characterized by a prolonged latency. BCR-ABL transduction of IL-3(-/-) Sca-1(+) lin(-) BM cells initially activates GM-CSF and G-CSF production, factor independence, and the ability to generate phenotypically indistinguishable populations of mast cells. However, maintenance of factor independence, and p210(BCR-ABL) and STAT 5 activation beyond 4 to 6 weeks, requires rescue with an IL-3 transgene. The cultured BCR-ABL-transduced IL-3(-/-) cells also lack leukemogenic activity in vivo. These findings provide new evidence that IL-3 production is a rapid, sustained, and biologically relevant consequence of BCR-ABL expression in primitive hematopoietic cells with multilineage leukemogenic activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393460     DOI: 10.1182/blood-2002-05-1324

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.

Authors:  Stephane Wong; Jami McLaughlin; Donghui Cheng; Kevin Shannon; Lorraine Robb; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

2.  IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms.

Authors:  Lukas F Mager; Carsten Riether; Christian M Schürch; Yara Banz; Marie-Hélène Wasmer; Regula Stuber; Alexandre P Theocharides; Xiaohong Li; Yu Xia; Hirohisa Saito; Susumu Nakae; Gabriela M Baerlocher; Markus G Manz; Kathy D McCoy; Andrew J Macpherson; Adrian F Ochsenbein; Bruce Beutler; Philippe Krebs
Journal:  J Clin Invest       Date:  2015-05-26       Impact factor: 14.808

3.  BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.

Authors:  Masahiro Tokunaga; Sachiko Ezoe; Hirokazu Tanaka; Yusuke Satoh; Kentaro Fukushima; Keiko Matsui; Masaru Shibata; Akira Tanimura; Kenji Oritani; Itaru Matsumura; Yuzuru Kanakura
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

4.  The inducible tissue-specific expression of the human IL-3/GM-CSF locus is controlled by a complex array of developmentally regulated enhancers.

Authors:  Euan W Baxter; Fabio Mirabella; Sarion R Bowers; Sally R James; Aude-Marine Bonavita; Elisabeth Bertrand; Ruslan Strogantsev; Abbas Hawwari; Andrew G Bert; Andrea Gonzalez de Arce; Adam G West; Constanze Bonifer; Peter N Cockerill
Journal:  J Immunol       Date:  2012-09-28       Impact factor: 5.422

5.  Clonal competition in BcrAbl-driven leukemia: how transplantations can accelerate clonal conversion.

Authors:  Kerstin Cornils; Lars Thielecke; Doreen Winkelmann; Tim Aranyossy; Mathias Lesche; Andreas Dahl; Ingo Roeder; Boris Fehse; Ingmar Glauche
Journal:  Mol Cancer       Date:  2017-07-14       Impact factor: 27.401

6.  Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML.

Authors:  Jun Toda; Michiko Ichii; Kenji Oritani; Hirohiko Shibayama; Akira Tanimura; Hideaki Saito; Takafumi Yokota; Daisuke Motooka; Daisuke Okuzaki; Yuichi Kitai; Ryuta Muromoto; Jun-Ichi Kashiwakura; Tadashi Matsuda; Naoki Hosen; Yuzuru Kanakura
Journal:  Oncogene       Date:  2020-07-13       Impact factor: 9.867

7.  Ex vivo expansion of normal and chronic myeloid leukemic stem cells without functional alteration using a NUP98HOXA10homeodomain fusion gene.

Authors:  I Sloma; S Imren; P A Beer; Y Zhao; V Lecault; D Leung; K Raghuram; C Brimacombe; K Lambie; J Piret; C Hansen; R K Humphries; C J Eaves
Journal:  Leukemia       Date:  2012-07-16       Impact factor: 11.528

8.  AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.

Authors:  Liang L Zhou; Yun Zhao; Ashley Ringrose; Donna DeGeer; Erin Kennah; Ann E-J Lin; Guoqing Sheng; Xiao-Jiang Li; Ali Turhan; Xiaoyan Jiang
Journal:  J Exp Med       Date:  2008-10-20       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.